High interleukin‑8 and/or extracellular signal‑regulated kinase 2 expression predicts poor prognosis in patients with hepatocellular carcinoma

Deng,Youyuan; Ning,Zhijie; Hu,Zhiya; Yu,Qianle; He,Bin; Hu,Guohuang

doi:10.3892/ol.2019.10907

High interleukin‑8 and/or extracellular signal‑regulated kinase 2 expression predicts poor prognosis in patients with hepatocellular carcinoma

Authors:
- Youyuan Deng
- Zhijie Ning
- Zhiya Hu
- Qianle Yu
- Bin He
- Guohuang Hu
View Affiliations

Affiliations: Department of General Surgery, Affiliated Changsha Hospital of Hunan Normal University, Changsha, Hunan 410006, P.R. China, Department of Neurology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130013, P.R. China, Department of General Surgery, Third Hospital of Changsha, Changsha, Hunan 410015, P.R. China
Published online on: September 23, 2019 https://doi.org/10.3892/ol.2019.10907
Pages: 5215-5224
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin (IL)‑8 and extracellular signal‑regulated kinase (ERK) 2 play key roles in tumor progression, but the relationship between IL‑8 and/or ERK2 expression in hepatocellular carcinoma (HCC) tissues and postoperative recurrence or survival is unclear. The expression levels of IL‑8 and ERK2 in both HCC tissues and non‑tumor liver tissues were analyzed using the Oncomine™ database and immunohistochemistry assay. Reverse transcription‑quantitative PCR was then used to evaluate the expression levels of IL‑8 and ERK2 in the tumor tissues of 67 patients with HCC undergoing radical hepatectomy. Pearson's correlation, Kaplan‑Meier, Cox univariate and multivariate survival analyses were utilized to determine the correlation between IL‑8 and ERK2 expression in HCC tissues, and their potential prognostic significance. As indicated by the data from the Oncomine™ database, and the patient samples, IL‑8 and ERK2 were expressed at significantly higher levels in HCC tissues than in non‑tumor liver tissues (P<0.05). The rates of high IL‑8 and ERK2 expression in HCC tissues were 43.28 (29/67) and 34.33% (23/67), respectively, and the IL‑8 and ERK2 expression levels were positively correlated (r=0.764; P<0.001). Both ERK2 expression and IL‑8/ERK2 co‑expression were significantly associated with tumor size and differentiation (P<0.05). Additionally, high expression levels of IL‑8, ERK2 and IL‑8/ERK2 co‑expression were all significantly associated with poor overall survival (OS; P<0.05) and disease‑free survival (DFS; P<0.05). Multivariate Cox regression analysis also showed that high expression levels of IL‑8, ERK2, and IL‑8 and ERK2 were independent prognostic factors for OS and DFS (P<0.05). The results of the present study indicate a significant increase in the risk of recurrence and mortality in HCC patients with high expression levels of IL‑8 and/or ERK2, compared with patients with low expression. Therefore, IL‑8 and ERK2 may be predictors of postoperative prognosis in patients with HCC.

View Figures

View References

1	Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J and Xiang YB: Risk factors of hepatocellular carcinoma-Current status and perspectives. Asian Pac J Cancer Prev. 13:743–752. 2012. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen G, Yang L, Li B, Huang P, Chen D, et al: CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Inves. 122:2165–2175. 2012. View Article : Google Scholar
5	Cha C, Fong Y, Jarnagin WR, Blumgart LH and DeMatteo RP: Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 197:753–758. 2003. View Article : Google Scholar : PubMed/NCBI
6	Bosch FX, Ribes J, Diaz M and Cleries R: Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 127:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
7	Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
8	Zlotnik A and Yoshie O: Chemokines: A new classification system and their role in immunity. Immunity. 12:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
9	Yuan A, Chen JJ, Yao PL and Yang PC: The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci. 10:853–865. 2005. View Article : Google Scholar : PubMed/NCBI
10	Lazennec G and Richmond A: Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol Med. 16:133–144. 2010. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Wang L, Zhang M, Jin M, Bai C and Wang X: Potential mechanism of interleukin-8 production from lung cancer cells: An involvement of EGF-EGFR-PI3K-Akt-Erk pathway. J Cell Physiol. 227:35–43. 2012. View Article : Google Scholar : PubMed/NCBI
12	Mohamed MM: Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: A mechanism mediated by IL-8 signaling pathway. Cell Commun Signal. 10:32012. View Article : Google Scholar : PubMed/NCBI
13	Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, et al: The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther. 11:1353–1364. 2012. View Article : Google Scholar : PubMed/NCBI
14	Wang Y, Wang W, Wang L, Wang X and Xia J: Regulatory mechanisms of interleukin-8 production induced by tumour necrosis factor-α in human hepatocellular carcinoma cells. J Cell Mol Med. 16:496–506. 2012. View Article : Google Scholar : PubMed/NCBI
15	Harimoto N, Shirabe K, Abe T, Kajiyama K, Nagaie T, Gion T, Kuroda Y and Maehara Y: Interleukin-8 producing hepatocellular carcinoma with pyrexia. HPB Surg. 2009:4614922009. View Article : Google Scholar : PubMed/NCBI
16	Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
17	Cowley S, Paterson H, Kemp P and Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 77:841–852. 1994. View Article : Google Scholar : PubMed/NCBI
18	Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF and Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 265:966–970. 1994. View Article : Google Scholar : PubMed/NCBI
19	Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW and Baba HA: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 48:83–90. 2008. View Article : Google Scholar : PubMed/NCBI
20	Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P and Fisher R: Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med. 15:85–94. 2009. View Article : Google Scholar : PubMed/NCBI
21	Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX and Wang XW: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kamarajah SK, Frankel TL, Sonnenday C, Cho CS and Nathan H: Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A surveillance, epidemiology, end results (SEER) analysis. J Surg Onco. 117:644–650. 2018. View Article : Google Scholar
23	He L, Fan X, Li Y, Chen M, Cui B, Chen G, Dai Y, Zhou D, Hu X and Lin H: Overexpression of zinc finger protein 384 (ZNF 384), a poor prognostic predictor, promotes cell growth by upregulating the expression of Cyclin D1 in Hepatocellular carcinoma. Cell Death Dis. 10:4442019. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C, Yu WC and Fan ST: Interleukin-8 serum levels in patients with hepatocellular carcinoma: Correlations with clinicopathological features and prognosis. Clin Cancer Res. 9:5996–6001. 2003.PubMed/NCBI
26	Loosen SH, Schulze-Hagen M, Leyh C, Benz F, Vucur M, Kuhl C, Trautwein C, Tacke F, Bruners P, Roderburg C and Luedde T: IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies. Int J Mol Sci. 19(pii): E17662018. View Article : Google Scholar : PubMed/NCBI
27	Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng Z and Liu L: Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res. 46:5228–5236. 2018. View Article : Google Scholar : PubMed/NCBI
28	Nacinovic-Duletic A, Stifter S, Dvornik S, Skunca Z and Jonjic N: Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol. 30:230–239. 2008. View Article : Google Scholar : PubMed/NCBI
29	Nakopoulou L, Mylona E, Rafailidis P, Alexandrou P, Giannopoulou I and Keramopoulos A: Effect of different ERK2 protein localizations on prognosis of patients with invasive breast carcinoma. APMIS. 113:693–701. 2005. View Article : Google Scholar : PubMed/NCBI
30	Becher B, Spath S and Goverman J: Cytokine networks in neuroinflammation. Nature reviews. Immunology. 17:49–59. 2017.PubMed/NCBI
31	Morel PA, Lee REC and Faeder JR: Demystifying the cytokine network: Mathematical models point the way. Cytokine. 98:115–123. 2017. View Article : Google Scholar : PubMed/NCBI
32	Liu XL, Li FQ, Liu LX, Li B and Zhou ZP: TNF-α, HGF and macrophage in peritumoural liver tissue relate to major risk factors of HCC Recurrence. Hepatogastroenterology. 60:1121–1126. 2013.PubMed/NCBI
33	Peng Q, Li H, Lao X, Deng Y, Chen Z, Qin X and Li S: Association of IL-2 polymorphisms and IL-2 serum levels with susceptibility to HBV-related hepatocellular carcinoma in a Chinese Zhuang population. Infect Genet Evol. 27:375–381. 2014. View Article : Google Scholar : PubMed/NCBI
34	Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels EA, Caporaso NE and Harris CC: Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 103:1112–1122. 2011. View Article : Google Scholar : PubMed/NCBI